cisplatin + methotrexate + pemetrexed

This is a combination chemotherapy regimen consisting of three drugs—cisplatin, methotrexate, and pemetrexed. Each drug has distinct mechanisms of action but collectively targets rapidly dividing cells such as cancer cells. Cisplatin is a platinum-based agent that forms DNA crosslinks, leading to cell death. Methotrexate is an antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis. Pemetrexed (also known as Alimta) is another antifolate that inhibits multiple folate-dependent enzymes involved in nucleotide synthesis[1][3][5]. The combination has been explored in clinical trials for advanced non-squamous non-small cell lung cancer (NSCLC) with malignant pleural effusion, where intrapleural infusion of tumor cell-derived microparticles packaging methotrexate was combined with systemic pemetrexed-cisplatin chemotherapy[2]. There is no widely recognized brand name or code name for this specific three-drug combination.

Other names

cisplatin and methotrexate and pemetrexedpemetrexed-cisplatin-methotrexate